TrialBMC medicine2022

Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II-III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial.

Xinsheng Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.